Dongliang Bian

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing

Junjie Hu, Lele Zhang, Haoran Xia et al. · Genome Medicine · 2023 · 380 citations · Full text

Medicine, Immunology, Oncology +17

Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

Yilv Yan, Dongqing Sun, Junjie Hu et al. · Nature Genetics · 2024 · 130 citations

Medicine, Bioinformatics, Oncology +14

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Xinsheng Zhu, Liangdong Sun, Nan Song et al. · BMC Medicine · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study

Dongliang Bian, Feng Zhou, Weiguang Yang et al. · Oncotarget · 2018 · 44 citations · Full text

Medicine, Oncology, Surgery +17

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

Dongliang Bian, Liangdong Sun, Junjie Hu et al. · Nature Communications · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17